C
9.80
0.31 (3.27%)
| Previous Close | 9.49 |
| Open | 9.77 |
| Volume | 323,462 |
| Avg. Volume (3M) | 4,764,126 |
| Market Cap | 85,286,656 |
| Price / Book | 2.10 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Profit Margin | -167.29% |
| Operating Margin (TTM) | -334.91% |
| Diluted EPS (TTM) | -2.02 |
| Quarterly Revenue Growth (YOY) | -13.20% |
| Current Ratio (MRQ) | 11.11 |
| Operating Cash Flow (TTM) | -16.53 M |
| Levered Free Cash Flow (TTM) | -10.69 M |
| Return on Assets (TTM) | -42.95% |
| Return on Equity (TTM) | -69.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | CervoMed Inc. | Bearish | Bearish |
AIStockmoo Score
-1.0
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -3.0 |
| Average | -1.00 |
|
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 33.38% |
| % Held by Institutions | 17.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cornerstone Wealth Management, Llc | 31 Dec 2024 | 20,650 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (Canaccord Genuity, 114.29%) | Buy |
| Median | 15.00 (53.06%) | |
| Low | 10.00 (D. Boral Capital, 2.04%) | Buy |
| Average | 16.00 (63.27%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 8.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 26 Mar 2025 | 10.00 (2.04%) | Buy | 7.71 |
| 17 Mar 2025 | 10.00 (2.04%) | Buy | 9.05 | |
| Canaccord Genuity | 18 Mar 2025 | 21.00 (114.29%) | Buy | 9.34 |
| Chardan Capital | 18 Mar 2025 | 14.00 (42.86%) | Buy | 9.34 |
| 13 Mar 2025 | 14.00 (42.86%) | Buy | 5.79 | |
| Roth MKM | 18 Mar 2025 | 20.00 (104.08%) | Buy | 9.34 |
| 11 Mar 2025 | 15.00 (53.06%) | Buy | 2.36 | |
| Jones Trading | 13 Mar 2025 | 15.00 (53.06%) | Buy | 5.79 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |